Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Exp Eye Res. 2008 Nov 1;88(3):418–425. doi: 10.1016/j.exer.2008.10.010

Fig. 3.

Fig. 3

Representative MR images of (a) control (no eye treatment), (b) at 50 min after passive delivery (passive control), and (c) at 45 min, 2.5 h, 12.5 h, and 14.5 h, from left to right, respectively, after 20-min 4-mA transscleral iontophoresis of Galbumin™ (concentration in the device ≈ 100 mg/ml) in vivo.

HHS Vulnerability Disclosure